Loading
A phase 3 trial testing Aglatimagene besadenovec in non-small-cell lung cancer, now recruiting.
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) is a phase 3 interventional study registered as NCT07660094, led by Candel Therapeutics, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment. Planned enrolment is 500 participants (estimated). The study started in 2026-06-15 and primary completion is expected in 2031-10-22. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aglatimagene besadenovec, Candel Therapeutics, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/